

Overview, 108-109

Pathologic evaluation, 113-114

Radiation therapy, 122-123

Research questions, 124-125

Surgical considerations, 110-112

Treatment selection, 114-122

# **Breast cancer diagnosis and management standards (invasive), 83-107**

Follow-up care, 100-102

Irradiation techniques, 98-100

Literature review, 83-88

Patient selection and evaluation, 88-95

Research areas, 102

Surgical treatment, 95-98

# **Breast problems, evaluation of by primary care physician, 49-63**

Background, 49-50

Cancer screening, 52-53

Diagnostic evaluation, 53-56

Evaluation and management, 56-60

Management summary, 61-63

Medical history, 50-51

Physical examination, 51-52

## **C**

### **CA—A Cancer Journal for Clinicians**

Address change for, 133, 256

**Cancer statistics**, 6-29, 31-48, 192 (erratum), 329 (erratum). See also National Cancer Data Base

Age level, 15, 16, 18-19, 28-29

Changing Trends, 3-4 (Guest Editorial)

Ethnic differences, 22, 24, 25, 31-48

Gender differences, 10, 11, 14, 15, 16-17, 34, 35, 38-42

Global view, 28-29, 192 (erratum)

Incidence, 12, 14, 33, 34, 36, 38, 43, 44, 45

Limitations and challenges, 8-9

Methods, 6-7

Mortality, 13, 14, 16, 18-19, 20, 21, 22, 26, 33, 35, 37, 43-45, 46

National Cancer Data Base: Ten Years of Growth and Commitment, 131-133 (Guest Editorial)

Pediatric, 26-28

Selected findings, 7-8

Stage at diagnosis, 24, 25

Survival rates, 23, 27

Survival rates, meaning of adjusted and observed, 189-190 (Letter)

### **Carbohydrate metabolism**

Nutritional support, 71-72

**Central nervous system tumors**, 331-360

Chemotherapy, 347-348

Classification, 331-333

Clinical manifestations, 337-338

Ependymomas, 354-355

Familial syndromes, 337

Glioblastoma multiforme, 349-352

Investigational approaches, 357-358

Malignant astrocytomas, 348-352

Medulloblastomas/primitive neuroectodermal tumors, 355-356

Meningiomas, 356-357

Molecular considerations, 333-336

Neuroimaging, 338-345

Overview, 331

Radiation therapy, 346-347

Surgical considerations, 345-346

What Have We Learned and Where Are We Heading?, 327-329 (Guest Editorial)

### **Chemotherapy**

Bladder cancer, 279-282

Central nervous system tumors, 328 (Guest Editorial), 347-348

Head and neck cancer (adjuvant therapy), 199-209

Laryngeal cancer, 214-220

Osseous metastases, 371-372

### **Childhood cancer**

Central nervous system tumors, 327, 328 (Guest Editorial)

National Cancer Data Base, 139

### **Cigarette smoking**

Bladder cancer, 265 (Guest Editorial)

Breast cancer risk factor, in women, 190-191 (Letter)

European Consensus Statement on Lung Cancer, 170-172

European tobacco advertising ban, 254-256

First-Ever Smoke-Free Cruise Ship, 261 (News & Views)

Head and neck cancer (adjuvant therapy), 205-206

Politics of addiction, status of tobacco settlement, 81-82

### **Cigar smoking**

New Anti-Cigar Campaign, 261 (News & Views)

Skyrocketing Cigar Use, 261 (News & Views)

### **Clinical trials**

Ten Things to Know about Clinical Trials, 262-263 (News & Views)

### **Colorectal cancer**

Incidence, 4 (Guest Editorial)

National Cancer Data Base, 139

### **Computed tomography**

Bladder cancer, 271

**Cryoablation**. See Prostate cryoablation

### **Cytology**

Bladder cancer, 271

## D

### Decreased nutrient intake

Nutritional support, 70-71

Diet. See Nutrition

**Ductal carcinoma in situ (DCIS) of breast.** See Breast cancer diagnosis and management standards (ductal carcinoma in situ)

## E

### Early detection

Bladder cancer, 265 (Guest Editorial)

Breast cancer, 52-56

### Editorials

Bladder Cancer: Twenty Years of Progress and the Challenges That Remain, 263-268 (Guest Editorial)

Central Nervous System Tumors: What Have We Learned and Where Are We Heading?, 327-329 (Guest Editorial)

Changing Trends, 3-4 (Guest Editorial)

Historical Perspective on Nutritional Support of Cancer Patients, 67-68 (Guest Editorial)

National Cancer Data Base: Ten Years of Growth and Commitment, 131-133 (Guest Editorial)

Squamous Cell Carcinoma of Head and Neck, Progress and Promise, 195-198 (Guest Editorial)

### Endometrial cancer management, 299-314

Epidemiology, 299-300

Estrogen replacement therapy, 312-313

Laparoscopic surgery, 305-306

Overview, 299

Postoperative surveillance, 309-312

Postoperative therapy, 306-308

Recurrent disease, 308-309

Staging, 302-305

Tamoxifen, 300-301

### Energy expenditure

Nutritional support, 71

### Enteral nutrition

Nutritional support, 74-76

### Ependymomas

Treatment, 354-355

### Errata

Cancer statistics, 192, 329

Prostate needle biopsy evaluation, 48

### Estrogen replacement therapy

Endometrial cancer management, 312-313

**Ethnic differences in cancer statistics, 31-48**

Data sources, 31-32

Limitations and challenges, 46-47

Mortality, 22

Overall rates, 32

Population profiles, 32-46

Prostate cancer in African-Americans, 315-319

Stage at diagnosis, 24, 25

Survival rates, 4 (Guest Editorial), 22, 25

### European Consensus Statement on Lung Cancer, 164-176

Commentary on, 164-166

Future studies, 172

Known risk factors, 167-168

Nutrition, 168-170

Nutritional recommendations, 173-174

Smoking and nutrition, 170-172

Study consequences, 172-173

### European Union

European tobacco advertising ban, 254-256

## F

### Fat metabolism

Nutritional support, 72-73

### Fine-needle aspiration

Breast problems, 54

## G

### Gamma knife treatment of brain tumors, 177-188

Complications, 185-186

Costs, 186

Metastatic brain tumors, 182-185

Overview, 177

Primary malignant tumors, 180-182

Technical aspects, 177-180

Value of, 186-187

### Gender differences in cancer statistics

Ethnic groups, 38-42

Incidence, 10, 14, 15, 16-17

Mortality, 11, 21

Survival rates, 4 (Guest Editorial)

### Genetics

American Cancer Society Second National Conference on Cancer Genetics, 107, 163

Bladder cancer, 271-272

Central nervous system tumors, 334-337

Head and neck cancer (adjuvant therapy), 205-206

Laryngeal cancer, 223

**Glioblastoma multiforme**

Treatment, 349-352

## H

**Head and neck cancer.** See also Laryngeal cancer

Laryngeal cancer, 211-228

**Head and neck cancer (adjuvant therapy), 199-209**

*Overview, 199*

*Prevention of new cancers, 205-206*

*Radiation therapy as primary treatment, 204-205*

*Squamous cell carcinoma of head and neck, 195-198*  
(Guest Editorial)

*Surgical management as primary treatment, 199-204*

**Hormonal therapy**

*Endometrial cancer management, 308-309, 312-313*

**Hypopharyngeal cancer**

*National Cancer Data Base, 140*

**I**

**Immunotherapy**

*Central nervous system tumors, 329* (Guest Editorial)

**International Union Against Cancer (UICC)**

*Role in European tobacco advertising ban, 254-256*

*Workshop on Nasopharyngeal Cancer, 64*

**Intravenous pyclography**

*Bladder cancer, 270-271*

**Invasive breast cancer diagnosis and management standards.** See Breast cancer diagnosis and management standards (invasive)

**Iodine 131.** See Thyroid doses of iodine 131

**L**

**Laryngeal cancer, 211-228**

*Cost of treatment options, 223-224*

*Extralaryngeal sites, 224-226*

*General considerations, 212-213*

*Historical review, 213-214*

*National Cancer Data Base, 141*

*Overview, 211-212*

*Treatment advances, 220-223*

*Treatment goals, 214*

*Treatment options, 214-220*

**Leadership Conference on Prostate Cancer in the African-American Community, 315-319**

**Letters**

*Breast cancer, smoking as risk factor for, in women, 190-191*

*Survival rates, meaning of adjusted and observed, 189-190*

**Literacy skill improvement, 151-162**

*Advice comprehensibility, 157-158*

*Assessment of readability levels, 155*

*Assessment of skills, 155*

*Communication improvement strategies, 156-157*

*Comprehension improvement strategies, 162*

*Mammogram instruction example, 156*

*Medical advice and patient match, 152-155*

*Medical advice comprehension, 152*

*Memory assistance techniques, 158-160*

*Overview, 151-152*

*Patient comprehension verification, 160*

*Recommendations, 160-161*

**Local field irradiation**

*Osseous metastases, 362*

**Lung cancer.** See also European Consensus Statement on Lung Cancer

*European Consensus Statement on Lung Cancer, 164-176*

*Incidence, 4* (Guest Editorial)

**M**

**Magnetic resonance imaging**

*Central nervous system tumors, 338-340*

**Malignant astrocytomas**

*Treatment, 348-352*

**Mammography**

*Breast cancer diagnosis and management (ductal carcinoma in situ), 109-110, 123-124*

*Breast cancer diagnosis and management (invasive), 89-90, 100-101*

*Breast problems, 53*

*Literacy skills improvement, 156*

**Medulloblastomas**

*Treatment, 355-356*

**Melanoma**

*Skin cancer prevention and screening, 232-235*

**Memory assistance techniques**

*Literacy skills improvement, 158-160*

**Meningiomas**

*Treatment, 356-357*

*National Cancer Data Base, 137*

**Metabolic alterations**

*Nutritional support, 71-73*

**Metastatic disease.** See also Osseous metastases

*Brain tumor, gamma knife treatment of brain tumors, 182-185*

*Osseous metastases, 361-374*

**N**

**Nasopharyngeal cancer**

*UICC Workshop on, 64*

**National Cancer Data Base, 134-145.** See also Cancer statistics

*American Joint Committee on Cancer Staging, 137*

*Brain cancer (meningioma), 137*

*Breast cancer: ductal carcinoma in situ, 138*

*Breast-preservation surgery, 138*

Childhood cancer, 139  
 Colorectal cancer, 139  
 Data completeness and comparability, 144  
 Data sources, 135-136  
 Geographical regions, 145  
 Hypopharyngeal cancer, 140  
 Laryngeal cancer, 141  
 Non-Hodgkin's lymphoma, 141  
 Ovarian cancer, 142  
 Overview, 134  
 Prostate cancer, 142  
 Quality management, 145  
 Renal cancer, 140  
 Stomach cancer, 143  
 Ten Years of Growth and Commitment, 131-133  
 (Guest Editorial)  
 Vulvar cancer, 143  
**National Cancer Institute.** See also Thyroid doses of iodine 131  
 Summary Report About Estimated Exposures and Thyroid Doses Received from Iodine 131 Fallout After Nevada Atmospheric Nuclear Bomb Tests, perspective on, 285-298  
**Nevada nuclear bomb tests.** See Thyroid doses of iodine 131  
**News & Views**  
 First-Ever Smoke-Free Cruise Ship, 261  
 The Five Most Important Things I'd Like to Tell Oncologists, Patients, and Family Members, ACS President's list, 259-260  
 New Anti-Cigar Campaign, 261  
 New Skin Cancer Prevention Group, 260-261  
 Skyrocketing Cigar Use, 261  
 Ten Things to Know about Clinical Trials, 262-263  
**Non-Hodgkin's lymphoma**  
 National Cancer Data Base, 141  
**Nuclear bomb tests.** See Thyroid doses of iodine 131  
**Nursing**  
 American Cancer Society Scholarships in Cancer Nursing, 268, 330  
**Nutrition**  
 Bladder cancer, 265 (Guest Editorial)  
 Lung cancer, European Consensus Statement on, 168-174  
**Nutritional support, 69-80**  
 Assessment, 73-74  
 Decreased nutrient intake, 70-71  
 Enteral nutrition, 74-76  
 Historical Perspective on Nutritional Support of Cancer Patients, 67-68 (Guest Editorial)  
 Metabolic alterations, 71-73  
 Oral nutrition, 74  
 Overview, 69

Total parenteral nutrition (TPN), 76-78

## O

**Open surgical biopsy**  
 Breast problems, 55-56  
**Osseous metastases, 361-374**  
 Analgesics, 362  
 Bisphosphonates, 363, 372  
 Bone-seeking radioisotopes, 363-365  
 Future research, 370-372  
 Local field irradiation, 362  
 New disease reduction, 368-369  
 Objective effects of treatment, 367-369  
 Overview, 361-362  
 Phosphorus 32, 365  
 Rhenium 186, 370-371  
 Rhenium 188, 370-371  
 Samarium 153 lexidronam treatment, 369-370  
 Strontium 89 chloride, 365-369  
 Subjective effects of treatment, 366-367  
 Toxicity of treatment, 369  
 Wide field irradiation, 362-363  
**Ovarian cancer**  
 National Cancer Data Base, 142

## P

**Paclitaxel**  
 Endometrial cancer management, 309  
**Pain**  
 Osseous metastases, 361-374  
**Pediatric cancer.** See Childhood cancer  
**Phosphorus 32**  
 Osseous metastases, 365  
**Politics**  
 Politics of addiction, status of tobacco settlement, 81-82  
 Thyroid doses of iodine 131, 285-298  
**Positron emission tomography (PET)**  
 Central nervous system tumors, 340-342  
**Primary central nervous system tumors.** See Central nervous system tumors  
**Primary malignant tumors**  
 Gamma knife treatment of brain tumors, 180-182  
**Primitive neuroectodermal tumors**  
 Treatment, 355-356  
**Prostate cancer**  
 African-Americans, 315-319  
 Clinical trial for evaluation, 250-251  
 Complications, 248-249  
 Histopathologic changes, 249-250

*Incidence, 3, 4 (Guest Editorial)*  
*Indications, 242*  
*Mechanisms of action, 241-242*  
*National Cancer Data Base, 142*  
*Osseous metastases, 267*  
*Overview, 239-241*  
*Prostate cryoablation, 239-253*  
*Prostate needle biopsy evaluation, 48 (erratum)*  
*Repeat treatment, 246*  
*Results, 246-248*  
*Salvage therapy following failure, 250*  
*Socioeconomic factors, 250*  
*Statistics, selected findings, 7, 8*  
*Techniques and patient care, 242-246*

## Q

### Quality management

*National Cancer Data Base, 145*

## R

**Racial differences.** See Ethnic differences in cancer statistics

**Radiation therapy.** See also Gamma knife treatment of brain tumors

*Breast cancer diagnosis and management (ductal carcinoma in situ), 110-112, 114-123*

*Breast cancer diagnosis and management (invasive), 98-100*

*Central nervous system tumors, 329 (Guest Editorial), 346-347*

*Endometrial cancer management, 306-309*

*Gamma knife treatment of brain tumors, 177-188*

*Head and neck cancer (adjuvant therapy), 199-209*

*Laryngeal cancer, 214-220*

*Osseous metastases, 362-363, 371-372*

**Radiotherapy decision-making criteria, 146-150**

*ACR Task Force on Appropriateness Criteria, 146-148*

*Background, 146*

*Oncology-related conditions, 148-150*

*Use of, 150*

### Rectal cancer

*Incidence, 4 (Guest Editorial)*

### Renal cancer

*National Cancer Data Base, 140*

### Rhenium isotopes

*Osseous metastases, 370-371*

## S

### Samarium 153 lexidronam treatment

*Osseous metastases, 369-370*

### Skin cancer prevention and screening, 232-235

*American Cancer Society, perspective on American College of Preventive Medicine's policy statements on, 229-231*

*American College of Preventive Medicine policy statements summarized, 232-235*

*Is the Ounce of Screening and Prevention Worth the Pound of Cure?, 236-238 (Viewpoint)*

*New Skin Cancer Prevention Group, 260-261 (News & Views)*

**Smoking.** See Cigarette smoking; Cigar smoking

### Social work

*American Cancer Society Training Grants in Clinical Oncology Social Work, 320*

### Socioeconomic status

*Ethnic differences, 47*

**Squamous cell carcinoma of head and neck (adjuvant therapy), 195-198 (Guest Editorial).** See also Head and neck cancer (adjuvant therapy)

### Staging

*American Joint Committee on Cancer Staging, NCDB, 137*

*Bladder cancer, 273-279*

*Endometrial cancer management, 302-305*

*Radiotherapy decision-making criteria, 148-150*

### Stereotactic biopsy

*Breast problems, 54-55*

### Stomach cancer

*National Cancer Data Base, 143*

### Strontium 89 chloride

*Osseous metastases, 365-369*

### Sunlight

*Skin cancer prevention and screening, 232-235, 237*

**Surgical management.** See also Prostate cryoablation

*Bladder cancer, 279-282*

*Breast cancer diagnosis and management (ductal carcinoma in situ), 110-112, 114-122*

*Breast cancer diagnosis and management (invasive), 95-98*

*Breast-preservation surgery, NCDB, 138*

*Central nervous system tumors, 345-346*

*Endometrial cancer management, 305-306*

*Head and neck cancer (adjuvant therapy), 199-204*

*Laryngeal cancer, 214-220*

*Prostate cryoablation, 239-253*

## T

### **Tamoxifen**

*Breast cancer diagnosis and management (ductal carcinoma in situ), 120-121*

*Endometrial cancer management, 300-301*

### **Thyroid doses of iodine 131, NCI report, 285-298**

*Background, 285-286*

*Critique, 295-296*

*Cumulative estimates, 290-292*

*Methodology, 286-290*

*Survival rates for patients with thyroid cancer, 294-295*

*Thyroid cancer and, 292-293*

*Thyroid nodules, evaluation of patients with, 293-294*

### **Tobacco settlement**

*Politics of addiction, status of tobacco settlement, 81-82*

### **Total parenteral nutrition (TPN)**

*Historical Perspective on Nutritional Support of Cancer Patients, 67-68 (Guest Editorial)*

*Nutritional support, 76-78*

### **Tumor markers**

*Bladder cancer, 271-272*

## U

### **Ultrasonography**

*Bladder cancer, 270*

*Breast problems, 53-54*

*Prostate cryoablation, 240, 244, 251*

### **Ultraviolet radiation**

*Skin cancer prevention and screening, 232-235, 237*

### **US Food and Drug Administration (FDA)**

*Politics of addiction, status of tobacco settlement, 81-82*

## V

### **Viewpoints**

*Is the Ounce of Screening and Prevention for Skin Cancer Worth the Pound of Cure?, 236-238*

### **Vulvar cancer**

*National Cancer Data Base, 143*

## W

### **Wide field irradiation**

*Osseous metastases, 362-363*

### **World Health Organization (WHO)**

*Central nervous system tumor classification, 331, 332-333*

*European Consensus Statement on Lung Cancer, 167*

## B

Bal DG, 164-166  
 Barakat RR, 299-314  
 Ben-Josef E, 361-374  
 Berger MS, 331-360  
 Biesalski HK, 167-176  
 Bland KI, 134-145  
 Bolden S, 6-29  
 Bueno de Mesquita B, 167-176  
 Byrne C, 189-190 (Letter)

## C

Cady B, 49-63, 191 (Letter)  
 Carew JF, 211-228  
 Cascade PN, 146-150  
 Chesson A, 167-176  
 Chytil F, 167-176  
 Copeland EM III, 67-68 (Guest Editorial)  
 Cox JD, 83-107  
 Cunningham MP, 134-145

## D

Daly JM, 69-80  
 Davis KJ, 31-48  
 Davis LP, 361-374  
 Doak CC, 151-162  
 Doak LG, 151-162  
 Doyle J, 239-253  
 Droller MJ, 269-284

## E

Evoy D, 69-80  
 Eyre HJ, 134-145, 315-319

## F

Fahey TJ III, 69-80  
 Feldman GE, 315-319  
 Ferrini RL, 232-235  
 Filipezak LA, 361-374  
 Fremgen A, 134-145  
 Friedell GH, 151-162

## G

Gardner B, 49-63  
 Goepfert H, 195-198 (Guest Editorial)  
 Grimble R, 167-176

## H

Heath CW Jr, 31-48  
 Hermus RJJ, 167-176  
 Hill L, 232-235  
 Hundahl SA, 285-298

## J

Jay SJ, 190-191 (Letter)

## K

Köhrle J, 167-176

## L

Lamm DL, 263-268 (Guest Editorial)  
 Landis SH, 6-29  
 Larison S, 239-253  
 Lawrence GA, 189 (Letter)  
 Laws ER Jr, 327-329 (Guest Editorial)  
 Lawson HW, 49-63  
 Lee NC, 49-63  
 Leibel SA, 146-150  
 Lieberman MD, 69-80  
 Lotan R, 167-176

## M

McDonald CJ, 229-231  
 Meade CD, 151-162  
 Menck HR, 134-145  
 Mertens WC, 361-374  
 Morrow M, 49-63  
 Murphy GP, 134-145  
 Murray T, 6-29

## N

Norpoth K, 167-176

## **P**

Parker SL, 31-48  
Partridge EE, 131-133 (Guest Editorial)  
Pastorino U, 167-176  
Porter AT, 361-374  
Prados MD, 331-360

## **R**

Ries LAG, 31-48  
Rigel DS, 236-238  
Rivadencira DE, 69-80  
Rosenthal DS, 3-4 (Guest Editorial)

## **S**

Schmidt JD, 239-253  
Seffrin JR, 81-82, 254-256  
Shah JP, 211-228  
Smart CR, 189-190 (Letter)  
Smith BL, 49-63

Smith RA, 189-190 (Letter)  
Steele GD Jr, 49-63  
Strom EA, 108-128

## **T**

Thurnham D, 167-176

## **V**

Vikram B, 199-209

## **W**

Wilson CB, 331-360  
Winchester DP, 49-63, 83-107, 108-128, 134-145  
Wingo PA, 6-29, 31-48

## **Y**

Young RF, 177-188



